AIDS Treatment News logo      

November 5, 2009

New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection

"A course of hepatitis C (HCV) combination therapy including the experimental HCV protease inhibitor telaprevir (VX-950) has produced a sustained viral response (SVR) in over 80% of treatment-naïve, hepatitis C-mono-infected patients with HCV genotype 1.

"Another study found similar rates achieved by another protease inhibitor, boceprevir. The findings were annouced on Tuesday at the American Association for the Study of Liver Disease (AASLD) meeting in Boston, USA."

Read more in Aidsmap, November 3, 2009.